|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In a multivariate analysis, the effects of GSTM1 null/GSTT1 null on survival were lost when residual disease and tumor grade were included.
|
11328408 |
2001 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We found the frequency of GSTT1 null genotype of 19.2% in cases and 15.7% in controls, with an adjusted odds ratio (OR) of 1.4 (95% confidence interval (CI), 0.70-2.81), and a frequency of GSTM1 null genotype of 59% in cases with oxyphilic tumors and of 55.6% in controls (OR 1.24; 95% CI, 0.62-2.48), indicating that the GSTT1 and M1 null genotypes do not increase the risk of development of oxyphilic tumors.
|
16427734 |
2006 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
GSTT1 deletion was nearly significantly more common among glioblastoma cases with tumor p53 mutation than for those whose tumors did not have p53 mutation (OR 2.8; 95% CI 0.93-8.4; P = 0.07).
|
15006924 |
2004 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This meta-analysis suggests that GSTM1 null and GSTT1/GSTM1 double null polymorphisms might be significantly associated with an increased tumor response.
|
26577857 |
2016 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The GSTM1 and GSTT1 genotypes did not show any correlation with the risk of the de novo diagnosed neoplasms.
|
15382272 |
2004 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
GSTT1 mRNA expression was higher in muscle-invasive BC and high-grade cancers than in non-muscle-invasive BC and lower-grade tumors.
|
21079384 |
2011 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
It is suggested that the GSTT1 polymorphism may have an impact on the severity of the tumor and its location.
|
30106268 |
2018 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
GSTM1 and GSTT1 expression was also downregulated in stage wise pattern; stage 1 had 50% and 12.5% tissues showing down regulation of GSTM1 and GSTT1 genes respectively, both GSTM1 and GSTT1 had 55% tissues with down regulation in stage 2, similarly stage 3 had 60% tissues showing down regulation of these genes and stage 4 had 86% and 71% tumors.
|
21545198 |
2011 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Furthermore, NAT2 slow-acetylator, GSTM1 null, and GSTM1/GSTT1-double null genotypes were associated with higher tumor grade (P=0.001, 0.022, and 0.036, respectively), and only NAT2 slow-acetylator genotype was associated with higher tumor stage (P=0.007).
|
19303722 |
2009 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Tumor tissue (n=197) was later retrieved from hospital of diagnosis and assayed using multiplex PCR (GSTM1 and GSTT1) and PCR and RFLP analysis (GSTP1).
|
19748847 |
2009 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
More than one tumour at first presentation (P <0.0001, hazard ratio 2.72) and GSTT1 null (P = 0.028, hazard ratio 1.74) were associated with decreased time to next primary tumour presentation.
|
9276622 |
1997 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We conclude that the GSTP1 and GSTT1 genes could play a role in carcinogenesis in the breast, possibly through increased frequency of mutations in tumor suppressor genes such as p53.
|
11700265 |
2001 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We conclude that patients with carcinoma of the breast and inheritance of a combined gene deletion of GSTM1 and GSTT1 might bear an increased risk to develop a secondary therapy-induced hematologic neoplasia.
|
11792413 |
2002 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
With great interest, we read the paper "GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis" (by Hu XY et al.), which has reached important conclusions that GSTM1 null and GSTT1/GSTM1 double null polymorphisms might be significantly associated with an increased tumor response in breast cancer.The result is encouraging.
|
27444273 |
2016 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A significantly lower frequency of GSTT1 deletion in glioma patients compared to healthy controls indicates that GSTT1 deletion may exert a protective role against gliomagenesis, influence therapeutic response to intranasal perillyl alcohol treatment, and increase overall survival, especially considering tumor topography.
|
23765968 |
2013 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The contribution of cigarette smoking to sporadic colorectal cancer may differ according to molecular aspects of the tumor or according to glutathione S-transferase M1 (GSTM1) or glutathione S-transferase T1 (GSTT1) genotype.
|
15840612 |
2005 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A case control association study was carried out to investigate polymorphisms in genes CYP1A1 (3801T > C), GSTM1, and GSTT1 (null genotypes) and oral squamous cell carcinoma (OSCC), including a correlation with some histopathological findings (tumor size, lymph node invasion and degree of tumor differentiation).
|
18507050 |
2008 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We studied the association between tumor pathology and the expression profile of seven phase I and II drug metabolizing genes (CYP1A1, CYP1B1, ALDH3A1, AOX1, GSTP1, GSTT1 and GSTM3) and some of their proteins.
|
26580399 |
2015 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, GSTP1val(105)/val(105) was protective against asthma symptoms and GSTT1 null was associated with a subgroup of basal cell carcinoma patients who develop large numbers of primary tumours in clusters.
|
11535245 |
2001 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Using in situ hybridization, we then demonstrated that GSTT1 transcripts are expressed in neoplastic cells of both tumour types.
|
16874663 |
2006 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Both GSTM1*0 (16/26 (61%) versus 10/40 (25%); p=0.003, OR 5; 95% CI=2-14) and GSTT1*0 (12/26 (46%) versus 13/40 (33%); p=0.2, OR 2; 95% CI=0.6-5) were associated with a higher risk of diffuse tumor than of intestinal tumor.
|
18365908 |
2008 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Using restriction fragment length polymorphism (RFLP) analysis, we have examined a cohort of 597 French VC workers for polymorphisms in CYP2E1, ALDH2, GSTM1 and GSTT1 in relation to the occurrence of mutant oncogene and tumor suppressor gene biomarkers that are attributable to VC exposure.
|
17384900 |
2007 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Here, we have investigated the association of tobacco - betel quid chewing, HPV infection, GSTM1-GSTT1 null genotypes, and tumour stages with mitochondrial DNA (mtDNA) content variation in oral cancer patients.
|
23469236 |
2013 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Similarly, no significant differences were obtained if GSTT1 and/or GSTM1 null genotypes were analyzed in subgroups of control subjects and ovarian cancer patients between the ages of 20-40, 41-70 and 71-90 years and in individuals with a positive family history of neoplastic disease.
|
9751255 |
1998 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Thus, logistic regression analysis adjusted by tumor size revealed a positive association between GSTT1 deletion and recurrence risk in general BC (OR 4.25; p = 0.04), while GSTM1 was negatively associated with recurrence risk in ER/PR<sup>+</sup>HER2<sup>-</sup> samples (OR 0.07; p = 0.03).
|
28455582 |
2018 |